BRIEF-Madrigal Pharmaceuticals Publishes Positive Results From Phase 3 Maestro-Nash Trial Of Rezdiffra

Reuters
30 Sep 2024

Sept 30 (Reuters) - Madrigal Pharmaceuticals Inc

:

* MADRIGAL PHARMACEUTICALS ANNOUNCES PUBLICATION OF POSITIVE HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE 3 MAESTRO-NASH TRIAL OF REZDIFFRA™ (RESMETIROM)

* MADRIGAL PHARMACEUTICALS INC - REZDIFFRA ACHIEVES PRIMARY ENDPOINTS IN PHASE 3 TRIAL

* MADRIGAL PHARMACEUTICALS INC - REZDIFFRA SHOWS SIGNIFICANT HRQL IMPROVEMENT COMPARED TO PLACEBO

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10